[
  {
    "ts": null,
    "headline": "Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain",
    "summary": "Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and why it is a Buy.",
    "url": "https://finnhub.io/api/news?id=9edeb1828d8f97fda559e4147f2b55e99e0d22649494f45d438b2e6bca901cee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738448271,
      "headline": "Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain",
      "id": 132512854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171631791/image_171631791.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and why it is a Buy.",
      "url": "https://finnhub.io/api/news?id=9edeb1828d8f97fda559e4147f2b55e99e0d22649494f45d438b2e6bca901cee"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank",
    "summary": "Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently approved by the FDA, which was widely expected, but the initial daily price of $31 is a bit above the threshold of $8 per day the firm’s key opinion leaders cites as the limit to ensure broad uptake, the analyst tells investors. Journavx’s value proposition as an opioid alternative, however, should not b",
    "url": "https://finnhub.io/api/news?id=a6e624bd87e5c577763a8094dd2a3ea171159387c6096e34a70e5188eb25b6d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738418721,
      "headline": "Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank",
      "id": 132631711,
      "image": "https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently approved by the FDA, which was widely expected, but the initial daily price of $31 is a bit above the threshold of $8 per day the firm’s key opinion leaders cites as the limit to ensure broad uptake, the analyst tells investors. Journavx’s value proposition as an opioid alternative, however, should not b",
      "url": "https://finnhub.io/api/news?id=a6e624bd87e5c577763a8094dd2a3ea171159387c6096e34a70e5188eb25b6d7"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine",
    "summary": "Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.",
    "url": "https://finnhub.io/api/news?id=cbbf2320ee5c9baf20089e6ab46b37affc06a54f1a3ee03d7d693d3897db75be",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738396800,
      "headline": "Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine",
      "id": 132510138,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186971023/image_2186971023.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.",
      "url": "https://finnhub.io/api/news?id=cbbf2320ee5c9baf20089e6ab46b37affc06a54f1a3ee03d7d693d3897db75be"
    }
  }
]